Document is current

Any future updates will be listed below

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Crossref DOI link: https://doi.org/10.1186/s12885-016-2559-8

Published Online: 2016-07-25

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark